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Background: Early disease detection with a minimally invasive screening test will significantly increase effectiveness
and decrease the cost of treatment. Here we propose a framework of a novel approach – Universal Screening Test
(UST) for the detection of pathological processes in a particular organ system, organ, or tissue by RT-qPCR analysis
of circulating cell-free miRNAs in plasma. As the first step towards assessing the feasibility of this concept, the present
study was designed to analyze whether the same microRNAs (miRNAs) can detect various diseases of a particular
organ system.
Methods: RNA was extracted from plasma using Trizol treatment and silica binding. Levels of miRNAs were measured
by single target RT-qPCR. The following innovations have been tested and proven effective: (i) the use of organ system/
organ/tissue-enriched miRNAs; (ii) the use of miRNAs associated with broad disease categories, such as cancer and
inflammation, in combination with the organ-enriched miRNAs; and (iii) the use of “miRNA pairs” for selecting miRNA
combinations with the highest sensitivity and specificity.
Results: Here we report biomarker miRNA pairs effectively differentiating (i) patients with pulmonary system diseases
(asthma, pneumonia and non-small cell lung cancer) and gastrointestinal (GI) system diseases (Crohn’s disease, stages
I/II esophageal, gastric and colon cancers) from controls, each with 95% accuracy; (ii) patients with a pathology of the
pulmonary system from patients with a pathology of the GI system with 94% accuracy; and (iii) cancer patients (stages
I/II esophageal, gastric, colon cancers, or non-small cell lung cancer) from patients with inflammatory diseases (asthma,
pneumonia, or Crohn’s disease) with 93%-95% accuracy.
Conclusions: The results obtained in the present study, along with the data reported by us and others previously, are
encouraging and lay the ground for further investigation of the described approach for UST development.
Keywords: Biomarker, miRNA, Circulating miRNA, miRNA pairs, Cancer, Inflammation, Pulmonary system,
Gastrointestinal system, Plasma, ScreeningBackground
It is well accepted that treatment of a disease is more
effective if an underlying pathology is diagnosed early.
For some diseases, early diagnosis, preferably made
prior to manifestation of clinical symptoms, is of critical
importance, because of pathology’s progression to an
advanced, sometimes irreversible, stage. For example,
one of the major problems facing drug development and
treatment of Alzheimer’s and other neurodegenerative
diseases is their late clinical manifestation: due to high* Correspondence: sumansky@diamirbio.com
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article, unless otherwise stated.compensatory potential of the brain the diseases are
usually diagnosed when many neurons are already dead
[1]. As a consequence, current treatments aim to delay
or prevent worsening of the pathology, rather than to
reverse the course of the disease. Another example is
cancer, where treatment of an invasive and metastatic
disease is much more difficult than treatment of a primary
tumor [2,3].
A major advantage of many existing screening tests is
their disease-specificity. However, there are hundreds of
human diseases, and it is difficult to envisage the devel-
opment of a specific screening test for each pathology.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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human diseases were developed, application of a large
number of tests for screening of broad populations will
likely be impractical due to limited accuracy and high
costs. For example, if a screening test for a disease with
prevalence 1:10,000 is 100% sensitive and 99% specific
(i.e. highly accurate) and 1 million people are screened,
100 cases would be detected correctly but about 10,000
people would receive false positive results. Concurrent
application of a large number of even highly accurate
tests will therefore result in a large number of false
positive predictions. These considerations provide a
motivation for the work reported herein.
In this paper we describe a framework for the devel-
opment of a novel approach to screening, which specif-
ically detects the presence of a pathological process in
a particular organ system, organ, tissue, and/or cell type
without diagnosing a particular disease. Testing with
UST could be performed periodically to detect presence
of pathology in a particular organ or organ system of a
person early, preferably at clinically asymptomatic stage.
Such testing would then be followed by more expensive
and possibly invasive diagnostic tests for a more specific
diagnosis.
UST should satisfy a number of criteria. First, because
the test will address a large population, it should be
minimally invasive or noninvasive. Secondly, UST should
not be based on inducing factors or pathogenesis of
diseases, since these are specific to a particular disease
and cannot be accounted for in a single test. Thirdly,
UST should be cost efficient - utilize a limited number
of biomarker types, which can be analyzed by the same
technique.
Biomarkers suitable for UST should possess the follow-
ing properties: (i) cell/tissue/organ-specificity or significant
enrichment; (ii) ability to appear in extracellular space
and to pass various barriers within the body; (iii) pres-
ence and reliable detectability in bodily fluids that can
be obtained by minimally invasive methods; and (iv)
stability. Certain tests currently used in clinical practice
employ biomarkers with many characteristics of potential
UST biomarkers, e.g. measurement of liver enzymes, or
of cardiomyocyte-specific proteins circulating in the
bloodstream for the detection of liver and heart path-
ologies, respectively.
We hypothesized that miRNAs are suitable candidates
to serve as UST biomarkers. miRNAs are stable small
molecules (~22 nt), which can cross blood–brain, kidney,
and placenta barriers and appear in the extracellular
space and bodily fluids [4,5]. Some of the methods used
for analysis of miRNAs, such as real-time reverse transcrip-
tion quantitative polymerase chain reaction (RT-qPCR),
are specific and sensitive [6]. Most importantly, miRNAs
constitute a large class of diverse molecules with somemiRNAs enriched in particular organ systems, organs,
tissues and cells [7-11].
Although mechanisms of miRNA appearance in the
extracellular space and subsequently in the bodily fluids
are not well understood, a role of cell death, blebbing,
exosome secretion and of other forms of active secretion
has been demonstrated [12,13]. Recently we have shown
that Mild Cognitive Impairment (MCI), a heterogeneous
syndrome characteristic of early stages of various neurode-
generative diseases, including Alzheimer’s and Parkinson’s
diseases, can be detected by analysis of brain-enriched
miRNAs in plasma [14].
Two novel elements were seen as essential: (i) identifi-
cation of potential biomarkers among organ-enriched
miRNAs, whose changes in plasma concentrations are
likely to be caused by a pathology of the respective
organ, and whose expression in blood cells is usually low,
the latter preventing contamination of these circulating
miRNAs due to hemolysis; and (ii) analysis of miRNA
ratios to identify pairs providing the best sensitivity and
specificity.
In the present feasibility study we demonstrate that
the same approach can be used to detect diseases of two
other organ systems, GI and pulmonary systems, and to
differentiate the gastrointestinal pathologies from the
pathologies of the pulmonary system. While the primary
disease target of the presented approach is detection of
cancer, to demonstrate that same approach can be used




K2EDTA (Ethylenediaminetetraacetic acid dipotassium)
plasma samples from 70 patients and 30 controls were
obtained from a commercial vendor Bioreclamation
(Westbury, NY). The samples were collected in compli-
ance with Health Insurance Portability and Accountabil-
ity Act (HIPAA), and a written consent was obtained
from each subject. DiamiR employees had no access to
private patient information. Blood samples were centri-
fuged at 2,100xg for 15 min at 4°C, aliquoted and frozen
at -20°C within 2 hours from blood collection, then
transferred to -80°C, and stored and shipped at -80°C.
Demographic characteristics of the study groups are
shown in Additional file 1: Table S1.
Plasma RNA extraction and RT-qPCR miRNA analysis
miRNA isolation and RT-qPCR analysis in all experiments
were performed by Asuragen Inc. according to the follow-
ing protocol. RNA was extracted from 200 μl aliquots
using Asuragen’s proprietary protocol, which is based on
Trizol treatment and silica (Ambiom Glass Fiber Micro-
column) binding. Single target RT-qPCR was performed
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Biosystems (AB) Catalog number 4366596) and miRNA-
specific stem-loop primers (see Additional file 1: Table S2
for AB Catalog IDs). RT step was performed in triplicate
and 2 μl plasma equivalents were present in final PCR
performed in ABI 7900HT instrument. Cq were deter-
mined with SDS v2.3 software. Placental RNA was used as
a “positive control” and No-Template controls were run as
a “negative control” with every run. The concentrations
of the 18 miRNAs (see Additional file 1: Table S2) were
determined in the plasma samples of patients and controls
as described in Results.
Statistical methods
In addition to biological factors, such as levels of miRNA
expression and secretion and blood supply to different
organs, miRNA yield from plasma and the level of RT-
PCR inhibitors in the blood of a given subject affect
miRNA measurements [15]. Therefore, data normalization
is an issue of critical importance. Herein, we employ the
“biomarker miRNA pair” approach used in our previous
study [14] and by others [16,17]: normalization is based
on an experimental search for miRNA pairs, which most
effectively differentiate two populations, e.g. pathology
versus control; to this end, ratios of levels of all possible
miRNA pairs from the same sample are calculated (2-ΔCq)
and the most promising pairs are selected. The advantage
of this approach is that in certain cases miRNAs, whose
concentrations are changed due to a pathology in opposite
directions, can form a pair effectively differentiating inves-
tigated populations.
All statistical calculations were performed with the use of
custom software developed at DiamiR [14]. Mann–Whitney
U-tests were used to evaluate significance of differentiation
of any two patient groups by various biomarker miRNA
pairs. Bonferroni correction was applied for estimating
significant P-values. In experiments on differentiation
of GI and pulmonary system pathologies from control
8 miRNAs were tested, thus P-value < 0.0018 (calculated
as 0.05/28; 28 here indicates the total number of miRNA
pairs examined) was considered significant. In experiments
on differentiation of diseases of GI system from the diseases
of pulmonary system and on differentiation of cancers
and inflammatory diseases 18 miRNAs were tested,
thus P-value < 0.0003 (calculated as 0.05/153; 153 here
indicates the total number of miRNA pairs examined)
was considered significant.
A standard formula for a case–control study [18] pro-
vides an estimate of the sample size required to produce
a certain statistical power (usually between 0.80 and
0.90). For the P-values given in the paragraph above, and
the ratio of difference between averages for comparison
groups to standard deviation of 2, the sample size cal-
culated according to ref. 18 to provide for power = 0.95is 42 samples for the detection of GI and pulmonary
system pathologies, 52 samples for the differentiation
of pathologies of two organ systems, and 52 samples
for the differentiation of cancers from inflammatory
diseases. In the present study, a higher number of samples
(50 samples for the detection of pulmonary system path-
ologies, and 70 samples in all other experiments) was used
to assure high power of the statistical test.
Receiver-Operating Characteristic (ROC) curves were
constructed and the area under ROC curves (AUC) was
calculated to evaluate sensitivity and specificity of vari-
ous miRNA pairs. Sensitivity and specificity are reported
for the cutoff points on the ROC curves, which provide
the best overall accuracy.
Results
Selection of miRNAs
Potential organ-enriched biomarker miRNAs were selected
according to the following two-step process. First, miRNAs
reported in the literature [7-11] to be enriched (when
compared with other organ systems) in normal tissues
and organs of pulmonary and GI systems were selected.
Second, we examined published reports describing ana-
lyses of circulating cell-free miRNAs in plasma and serum
[19-22] and selected from the pool of miRNAs chosen in
the first step only miRNAs reported to be detectable in
the bloodstream. The second step in the selection process
is critical, since levels of miRNA expression in various
tissues generally do not correlate with their concentrations
in plasma or serum [23,24], and the plasma levels of
tissue-enriched miRNAs are usually significantly lower
than the levels of ubiquitous miRNAs. The miRNAs
selected for testing are listed in Additional file 1: Table S2.
miRNAs shown to be involved in carcinogenesis and
inflammation [25-29] were also included in the analysis
(see Additional file 1: Table S2), so as to investigate a
possibility of differentiating these most common types of
pathological processes.
Detection of GI system pathologies
Plasma samples were obtained from 40 patients with
pathologies of the GI system (esophageal, gastric and
colorectal cancers, stages I and II, and Crohn’s disease,
10 patients in each group) and 30 healthy controls (see
Additional file 1: Table S1). The levels of miR-145, miR-
148a, miR-192, miR-194, miR-203, and miR-215, enriched
in organs of the GI system, as well as of ubiquitous
miR-30e-3p and miR-181a (see Additional file 1: Table
S2) were determined by the single target TaqMan® miRNA
RT-qPCR assay. The ratios of all possible miRNA pairs
were calculated (2-ΔCq) and the ability of each pair to
differentiate patients with a GI pathology from controls
was analyzed (see Methods). Using sums of two or
more miRNAs in the numerator or denominator of a
Figure 1 (See legend on next page.)
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Figure 1 Differentiation of GI pathologies from controls by miRNA biomarker pairs. The concentrations of miRNAs in plasma samples of
patients with four GI pathologies, and healthy donors were measured by RT-qPCR and the ratios of levels of various miRNAs were calculated as
2-ΔCq x 100. A-E – box-plots. Here and in other figures with box and whisker plots the results are presented in the log10 scale. The upper and
lower limits of the boxes and the lines inside the boxes indicate the 75th and 25th percentiles and the median, respectively. The upper and lower
horizontal bars denote the 90th and 10th percentiles, respectively. The points indicate assay values located outside of 80% data. A-D – individual
pathologies (10 patients in each group) against controls (30 subjects); E – combined GI pathologies (40 patients total) against controls (30 subjects).
F –ROC curves of differentiation between patients with four GI pathologies and controls obtained with different biomarker pairs. The areas under the
ROC curves (AUC) are reported. Sensitivity, specificity and accuracy for each miRNA pair are calculated for the “cutoff” point (indicated as a dot on each
plot) – the value of the ratio where the accuracy of predictions is the highest (see Methods, ref. 14).
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only biomarker miRNA pairs and their combinations
are presented. Figure 1 and Additional file 1: Figure S1
demonstrate that certain miRNA pairs effectively differen-
tiate patients with the GI pathologies from controls – both
when all pathologies are grouped together, and when
analyzed separately. These effective pairs include GI
system-enriched miRNAs and ubiquitous miR-30e-3p,
and GI system-enriched miRNAs paired with each other.
The ROC curves for selected miRNA pairs and their
combination are presented in Figure 1, panel F. The areas
under the ROC curve (AUC) for miR-215/miR-30e-3p,
miR-215/miR-145 and miR-203/miR-145 are 0.97-0.99,
and overall accuracy is 90%-96%. P-values presented in
Table 1 are 106-107 times lower than P = 0.0018 consid-
ered significant with Bonferroni correction (see
Methods). Additional file 1: Figure S1, panel H reports
additional miRNA pairs able to effectively differentiate
patients with the GI pathologies from controls.Table 1 Differentiation of various groups of patients from ea
miRNA pairs
Groups of subjects compared
GI system diseases versus controls
Pulmonary system diseases versus controls
GI system diseases versus Pulmonary system diseases
Cancers versus Inflammatory diseases
All P-values given in the table are highly statistically significant. The threshold for st
“GI system diseases versus controls” and for “Pulmonary system diseases versus con
and for “Cancers versus Inflammatory diseases” (see Methods).Detection of pulmonary system pathologies
Plasma samples were obtained from 30 patients with path-
ologies of the pulmonary system (asthma, pneumonia
and non-small cell lung cancer (NSCLC), stages I - IV,
10 patients in each group) and 20 healthy controls (see
Additional file 1: Table S1). Among 20 controls, 10 were
smokers and 10 were non-smokers. A smoking status
appeared not to affect detection of pulmonary pathologies,
and we used the combined control group for the study.
The levels of miR-34b, miR-142-5p, miR-146b-5p, miR-
155, miR-223, and miR-486-5p, enriched in the pulmonary
system, as well as of ubiquitous miR-409-3p and of miR-
192, which is enriched in the GI system, but is also broadly
expressed in other organs including pulmonary system
(see Additional file 1: Table S2), were determined by the
single target TaqMan® miRNA RT-qPCR assay. The ratios
of all possible miRNA pairs were calculated (2-ΔCq) and
their ability to differentiate patients with a pulmonary
pathology from controls was analyzed. Figure 2, Table 1,ch other, and from healthy controls with the identified

















atistical significance, as calculated with the Bonferroni correction, is 1.8E-03 for
trols”; and 3.0E-04 for “GI system diseases versus Pulmonary system diseases”
Figure 2 Differentiation of Pulmonary system (PS) pathologies from controls by miRNA biomarker pairs. The concentrations of miRNAs in
plasma samples from patients with three PS pathologies, and from healthy donors were measured by RT-qPCR and the ratios of various miRNAs
were calculated as 2-ΔCq x 100. A-E – box-plots; A-D – individual pathologies (10 patients in each group) against controls (20 subjects); E – combined
PS pathologies (30 patients total) against controls (20 subjects). F –ROC curves of differentiation between patients with three pathologies and controls
obtained with different biomarker pairs. The statistical analysis is performed as in Figure 1.
Sheinerman et al. Journal of Translational Medicine 2013, 11:304 Page 6 of 12
http://www.translational-medicine.com/content/11/1/304
Sheinerman et al. Journal of Translational Medicine 2013, 11:304 Page 7 of 12
http://www.translational-medicine.com/content/11/1/304and Additional file 1: Figure S2 demonstrate that certain
miRNA pairs effectively differentiate patients with the pul-
monary system pathologies from controls – both when all
pathologies are grouped together, and when analyzed
separately. These effective pairs include pulmonary
system-enriched miRNAs paired with ubiquitous miR-
409-3p, and pulmonary system-enriched miRNAs paired
with each other.
Unexpectedly, miR-192, which is not enriched in the
pulmonary system, paired with various miRNAs also
distinguished patients with pulmonary pathologies from
controls (see Additional file 1: Figure S2, panels C-F
and K-L). This effect is most likely caused by miR-192
overexpression in lung cancer and possibly other pul-
monary pathologies [30,31].
The ROC curves for selected miRNA pairs and their
combinations are presented in Figure 2, panel F and
Additional file 1: Figure S2, panels J and L. The areas
under the ROC curves (AUC) for miR-486-5p/miR-409-
3p, miR-486-5p/miR-146b-5p and miR-34b/mir-146b-5p
are 0.94-0.97, and overall accuracy is 90%-96%. P-values
presented in Table 1 are 103-107 times lower than
P < 0.0018 considered significant with Bonferroni cor-
rection (see Methods). Additional file 1: Figure S2
reports additional miRNA pairs able to effectively dif-
ferentiate patients with the pulmonary system patholo-
gies from controls.
Differentiation between pathologies of the GI and
pulmonary systems
In the next sets of experiments miRNA levels were mea-
sured in all plasma samples (40 samples of patients with
pathologies of GI system, 30 samples of patients with the
pulmonary system pathologies, and 30 healthy controls).
In addition to miRNAs enriched in GI and pulmonary sys-
tems and several ubiquitous miRNAs, miRNAs associated
with carcinogenesis and inflammation, the two types of
pathologies included in the present study, were also
analyzed (see Additional file 1: Table S2).
Figure 3 demonstrates that the ratios of several miRNA
pairs successfully differentiate pathologies of GI and
pulmonary systems. The ROC curves for some miRNA
pairs and their combinations are presented in Figure 3,
panels C and D. The areas under the ROC curves are 0.83-
0.99, and overall accuracy is 85%-96%. P-values presented
in Table 1 are much lower than P = 0.0003 considered
significant with Bonferroni correction (see Methods).
We have also tested the ability of selected miRNA pairs
to differentiate pathologies of organs of different organ
systems based on comparison of samples with a particular
disease of one organ with all pathologies of another organ
system grouped together. Additional file 1: Figure S3
represents respective ROC curves. The data demonstrate
high efficiency of this approach, further improved bycombinations of several biomarker pairs. AUC and overall
accuracy are in the ranges of 0.97-1.0 and 93%-100%,
respectively.
Differentiation between cancer- and inflammation-
associated pathologies
Figure 4 and Table 1 reports miRNA pairs differentiating
inflammation-associated pathologies (asthma, pneumo-
nia and Crohn’s disease) grouped together from cancer
(NSCLC, esophageal, gastric and colon cancers) with
87%-93% sensitivity, 93%-95% specificity, and 90%-94%
overall accuracy. P-values presented in Table 1 are 104-
106 times lower than P = 0.0003 considered significant
with Bonferroni correction (see Methods). The high values
obtained here for sensitivity, specificity, and accuracy
are particularly notable since cancer can be accompanied
by inflammation. The differentiation between two types
of pathologies is even stronger when analyzed for
GI and pulmonary systems separately (Additional file 1:
Figure S4): AUC is 0.99 and 1.0 for pulmonary and GI
systems, respectively.
Discussion
The goal of medical screening is the detection of a
disease in subjects at asymptomatic stages, which leads
to more effective treatment of the disease. Two major
considerations limiting application of screening tests are
economical and psychological in nature. From economical
perspective, the factors limiting the utility of screening
tests are: (i) cost, especially when large populations are
screened for rare diseases; and (ii) practically unavoidable
false positive results with additional expenses for subse-
quent diagnostic investigations. The latter issue also leads
to negative psychological effects, such as unwarranted
stress and anxiety.
To address these issues, we propose a novel approach
to screening, namely Universal Screening Test (UST), to
detect pathologic processes in organ systems, organs and
tissues. Such a test will not diagnose specific diseases,
but rather will detect the presence of a pathology in a
particular organ or organ system. Additional diagnostic
tests will then be applied to a limited number of subjects
pre-selected by UST. The present paper describes an
initial study demonstrating feasibility of detection of
various pathologies of a particular organ system by ana-
lysis of levels of circulating cell-free miRNAs in plasma.
There have been numerous attempts to develop screen-
ing and diagnostic tests based on analysis of circulating
miRNAs. In many cases samples from patients with a
particular disease were successfully differentiated from
controls [5,19,24,30]. However, such findings by them-
selves do not necessarily mean that the tests specifically
detect the disease. Many miRNAs are associated with a
common pathology type, e.g. cancer, inflammation, or
Figure 3 Differentiation of GI pathologies fromPS pathologies by miRNA biomarker pairs. The concentrations of miRNAs in plasma
samples from patients with GI pathologies (40 patients total) and pulmonary system pathologies (30 patients total) were measured by RT-qPCR
and the ratios of various miRNAs were calculated as 2-ΔCq x100. A, B – box-plots. C, D –ROC curves for differentiation between patients with the
four GI and the three pulmonary system (PS) pathologies obtained with different biomarker pairs. All statistical analyses are performed as in
Figure 1. E, F – 2D-graphs comparing biomarker miRNA pairs from A, C and B, D, respectively.
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Figure 4 Differentiation of all cancers from all inflammatory pathologies by miRNA biomarker pairs. The concentrations of miRNAs in
plasma samples from patients with cancers of four organs (40 patients total) and three inflammatory diseases (30 patients total) were measured
by RT-qPCR and the ratios of various miRNAs were calculated as 2-ΔCq x 100. A, B – box-plots. C, D – Receiver-Operating Characteristic (ROC) curves
of differentiation between patients with cancers of the four organs and patients with any of the three inflammatory diseases obtained with
different biomarker pairs. All statistical analyses are performed as in Figure 1. E, F – 2D-graphs comparing biomarker miRNA pairs from A, C
and B, D, respectively.
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described as potential biomarkers of different diseases.
For example, changes of miR-155 concentrations were
found in the bloodstream of patients with breast,
esophageal, lung, pancreatic cancers and lymphomas
[25,27]. Level of miR-21 increases in plasma/serum of
patients with osteosarcoma, bladder, esophageal, gastric,
lung, breast, colorectal cancers, neck squamous cell
carcinoma and other tumors [25-27]. Some miRNAs are
associated with both cancer and inflammation [29,32-35].
A large number of similar examples can be found in
literature. In summary, a mere differentiation of patients
with a disease from control subjects is not sufficient
for specific detection of a disease in a clinical setting.
Additional information, such as localization of a disease
in a particular organ, is required.
Here we proposed to analyze organ/organ system-
enriched miRNAs to differentiate pathological processes
of different organs, based on a hypothesis that changes
in their concentrations in plasma will most likely be
associated with a disease of a respective organ or organ
system. We also included in the study a number of
miRNAs involved in such broad classes of pathologies
as carcinogenesis and inflammation, to find out whether
analysis of the levels of these miRNAs along with the
levels of organ-enriched miRNAs can provide more
specific information about pathology.
In the current study analysis of miRNA ratios (miRNA
biomarker pairs) was performed to account for numerous
factors that affect detectable levels of various miRNAs:
miRNA stability in plasma, effectiveness of its purification,
potential RT-qPCR inhibition, etc. Further, calculation
of ratios of two miRNAs could increase sensitivity and
specificity of a biomarker panel, since expression and
secretion of different miRNAs may be affected differently
(e.g. changed in opposite directions) by pathology.
Two organ systems and seven pathologies were used to
test the proposed approach. The results obtained can be
summarized as follows: (1) analysis of organ system-
enriched miRNA levels in plasma effectively detected
patients with the pathologies studied: asthma, pneumonia
and NSCLC in pulmonary system and Crohn’s disease,
esophageal, gastric and colon cancers in GI system; it is
important to note that all 30 cancers of the GI system and
4 out of 10 NSCLC were in stages I/II (see Additional file
1: Table S1), providing a dataset with relatively early stages
of pathology; (2) miRNA pairs successfully differentiating
patients with pulmonary system diseases from patients
with the GI system diseases have been identified; and
(3) cancer patients were effectively distinguished from
patients with inflammatory diseases.
We have recently demonstrated that a similar approach
can be used for early detection of MCI, a syndrome char-
acteristic of early stages of various neurodegenerativediseases, including Alzheimer’s and Parkinson’s diseases
[14]. Two sets of biomarker miRNA pairs capable of
differentiating MCI from age matched controls with
82%-92% accuracy were found. These biomarkers were
then successfully validated in a larger study with independ-
ent cohorts of plasma samples, and accuracy obtained in
this validation study was 87% - 96% (poster presented in
2013 Alzheimer's Association International Conference;
Aging, manuscript in press). In addition, in a small retro-
spective longitudinal study we analyzed plasma samples
collected from the same patients at different time points
for up to 5 years and demonstrated that MCI can be de-
tected 1–5 years prior to clinical diagnosis [14]. The values
of miRNA biomarker pairs in plasma samples collected
from same subjects over the course of 1 to 5 years were
very consistent.
The most common approach to search for circulating
miRNA biomarkers of various diseases is miRNA array
analysis of numerous miRNAs in serum or plasma.
However, the concentrations of many organ-enriched
miRNAs in bodily fluids are too low to be detected by
miRNA arrays and, as a result, they can be missed in
such studies. Nonetheless, some of these miRNAs are
detectable and, in fact, these miRNAs are among the
most promising biomarkers due to increase of their
levels in plasma or serum. Circulating liver-enriched
miR-122 [36] and heart-enriched miR-1, miR-133, miR-
208 and miR-499 [37] represent good examples since
their concentrations have been found to be significantly
higher in the bloodstream of patients with various diseases
of respective organs. Interestingly, in some instances
concentrations of these miRNAs in organ tissues are
decreased due to pathology but their levels in plasma
or serum go up [38], which additionally supports the
idea of using organ-enriched miRNAs for detecting
pathology of respective organs.
Thus, the data obtained in the present study and the
results of literature analysis indicate that the idea of
Universal Screening Test presented herein is viable.
Naturally, larger studies involving patients with diseases
of GI and pulmonary systems, as well as accurately
matched control subjects, including cohorts with differ-
ent age, gender, and ethnicity, are necessary for further
validation of the approach. Longitudinal studies and
analysis of precancerous conditions, such as adenomatous
polyps, will help clarify how early various organ patho-
logies can be detected. It also would be important to com-
pare levels of these miRNA biomarkers in subjects before,
during and after treatment in order to evaluate their ap-
plicability to disease and treatment monitoring. Further,
studies with additional miRNAs and patients with path-
ologies of other organs should be performed.
Currently, data on miRNA expression in various or-
gans, tissues and cell types are still limited. Some
UST Summary
Sample (plasma, other bodily fluids) collection
miRNA purification
Measurement of miRNA concentrations 
Calculation of miRNA ratios and data analysis with specially developed software
Detection of organ system/organ pathology Detection of pathology type
Further diagnostic tests for specific diseases
Figure 5 The UST workflow.
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plasma levels of miRNAs not enriched in a certain organ
may increase due to higher expression or secretion
caused by pathology. The increase in concentration of
circulating miR-192 in patients with pathologies of pul-
monary system reported here (see Additional file 1: Fig-
ure S2) provides a good example of such an increase
caused by pathology. We believe that a potential ambigu-
ity with respect to organs or organ systems affected by
pathology, as inferred from analysis of certain miRNAs,
such as miR-192, can be overcome by measuring levels of
several miRNAs enriched in each organ system, organ and
tissue.
Figure 5 presents a diagram of the proposed UST work-
flow. Briefly, after measuring miRNA concentrations in a
bodily fluid, pathologies in one or several organ systems
are detected based on calculations of miRNA ratios. When
possible, a pathology type (e.g. cancer, inflammation) is de-
termined. If pathology is detected, specific diagnostic tests
should be performed.
Conclusions
The present paper describes an approach to the develop-
ment of Universal Screening Test for early detection
of pathological processes in a particular organ or organ
system based on analysis of circulating organ-enriched
miRNAs, and, as a feasibility study, reports identificationof plasma miRNA biomarkers for detection of diseases
of gastrointestinal and pulmonary systems.
Additional file
Additional file 1: Table S1. Demographics of plasma donors. Table S2.
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